AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02661152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimorazole
Description: Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
Study NCT02673983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness biopsy
Study NCT02347592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-locating Catheter
Description: Procedure/Surgery necessary if obstruction occurs
Study NCT02347592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: straight Tenckhoff
Description: Procedure/Surgery necessary if obstruction occurs
Study NCT02188719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsies
Description: Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
Study NCT01682109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Study NCT03855943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Computer Program
Description: Training with a personalized computerized inhibitory training program
Study NCT03855943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
Study NCT03293121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength and Coordination Training
Description: Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
Study NCT03293121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
Study NCT02217618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Study NCT03579758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT03579758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03579758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03579758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT03470350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: treatment with capecitabine and galunisertib
Study NCT01684670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech sessions
Description: Subjects will be instructed to use clear speech and increased effort when speaking.
Study NCT01868828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD
Description: Induction Therapy of PAD for 4 cycles.
Study NCT01868828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCD
Description: Induction Therapy of VCD for 4 cycles.
Study NCT01868828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Not suitable for transplant patients will continue accept treatment for 8 cycles.
Study NCT03443687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: Pelvic floor exercises for 3 months under instruction of physical therapist
Study NCT03443687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Biofeedback
Description: Pelvic floor exercises for 3 months using biofeedback device
Study NCT03775993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human growth hormone
Description: Administration of growth hormone
Study NCT03775993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study NCT02764996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT01196195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra dosed once daily
Description: Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
Study NCT01196195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kaletra dosed twice daily
Description: Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
Study NCT04161209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single dose administration of citalopram (20mg)
Study NCT04161209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo tablet
Study NCT05771532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Received the GS-SHEP
Description: The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy.
Study NCT00441766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
Study NCT00441766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
Study NCT00441766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
Study NCT00441766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: placebo capsule every 12 hours for 4 weeks
Study NCT00649350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 750 mg
Description: 750mg, single dose fed
Study NCT00649350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage XR 750 mg
Description: 750mg, single dose fed
Study NCT02748681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP AirSense™ 10(Resmed)
Description: AutoSet CPAP without telemedicine monitoring
Study NCT02640027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast removal at home using a telemedicine tool
Description: Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
Study NCT01306747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Stanford Chronic Pain Self-Management Programme
Description: The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
Study NCT00369837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
Study NCT02188719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
Study NCT02197572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.
Study NCT03758807 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Therapy with Traditional Biomechanical Explanation
Description: Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
Study NCT03758807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy with Neuroplastiicity Explanation
Description: Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
Study NCT04593121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.
Study NCT03077113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4-D CT Scan
Description: The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
Study NCT03077113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SPECT-CT Scan
Description: It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
Study NCT01557764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01557764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT02861755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
Study NCT02861755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-week Emotion Reporting
Study NCT00676793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Four 200mg capsules daily taken with a meal, for the duration of the study.
Study NCT04496648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques
Study NCT04496648 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-percutaneous coronary intervention
Description: Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
Study NCT03746067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-134
Description: 5 mg, 10 mg, or 20 mg oral solution
Study NCT03746067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo oral solution
Study NCT01992848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood sampling
Description: 40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
Study NCT01992848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-day food diary
Study NCT01992848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 week UV dosimeter
Description: To be worn on outerwear for one week week prior to attendance for pQCT
Study NCT01992848 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Peripheral Quantitative Computed Tomography of the radius
Description: To be performed within one month of attendance for CT coronary angiography
Study NCT01235728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 2% Cream
Description: Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
Study NCT01235728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 vehicle (placebo) Cream
Description: Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
Study NCT01235728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol Cream
Description: Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
Study NCT04269655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-Based Continuous Glucose Monitoring
Description: The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
Study NCT01899677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
Study NCT01899677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: symbiotic
Description: Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
Study NCT03841487 — intervention group
Intervention type: DEVICE
Intervention: Aspiration thrombectomy
Description: In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
Study NCT04150562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
Study NCT04593121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT05257382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy
Description: After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
Study NCT05257382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy
Description: After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
Study NCT03848416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT03186430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Vaccine Promotion Package
Description: Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room.
Study NCT03103854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BURST physical activity
Description: BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
Study NCT03103854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: Patients were sent daily text message reminders to remind them to exercise.
Study NCT03103854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Continuous Training
Description: This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
Study NCT03103854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
Study NCT05508828 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy
Description: All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
Study NCT01639469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: Structured exercise includes stretching, strengthening, and balance exercises.
Study NCT01639469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle exercise
Description: Subjects will be taught lifestyle exercises and advised about mobility strategies
Study NCT03256721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib/docetaxel/pemetrexed
Description: Participants are randomly assigned to treatment group or control group
Study NCT03256721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel/pemetrexed
Description: Participants are randomly assigned to treatment group or control group
Study NCT04150562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
Study NCT04316507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genetic Counselling and Testing
Description: Oncologist-initiated brief genetic counselling and testing
Study NCT02700672 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study: kinematic variables, falls and executive function were analyzed
Study NCT03155139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/renin ratio (ARR) testing
Description: Plasma aldosterone concentration tests, Direct renin concentration tests
Study NCT03155139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory tests
Description: Captopril challenge test, Saline infusion test
Study NCT03888014 — intervention group
Intervention type: DEVICE
Intervention: GLOW800
Description: The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
Study NCT03888014 — intervention group
Intervention type: DRUG
Intervention: indocyanine green (ICG)
Description: This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
Study NCT02156193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic clip
Description: Prophylactic clipping
Study NCT02156193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No prophylactic management
Description: No prophylaxis